PE 22-28

shortened spadin analogueCognition/Mood

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeNootropic / Mood

MechanismA synthetic heptapeptide derived from spadin that blocks the TREK-1 potassium channel, with an IC₅₀ of about 0.12 nM against spadin’s 40–60 nM.

EffectsAntidepressant-like effects in rodent behavioural models, with in vivo stability extended to roughly 23 hours against spadin’s 7.

DosingNo human dose established.

Bottom lineGenuinely interesting rodent pharmacology, no human trial.

Not a dose · what the literature contains instead

Reported practice is 100–300 mcg intranasally or subcutaneously once daily, which is community usage rather than a studied regimen.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

All efficacy evidence is from rodent models. Not approved for any use, and no human safety or pharmacokinetic data exists.

No human interaction data. TREK-1 blockade overlaps mechanistically with serotonergic antidepressant pathways, which has not been studied in combination.

CV 1 of 5 — No cardiovascular data.